Inozyme Pharma, Inc. Income Statement

Ask AI

Financial Statements

In millions of USD; shares in millions, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Operating expenses:
Research and development
General and administrative
Total operating expenses
Loss from operations
Other income (expense):
Interest income
Interest expense
Other expense, net
Other income, net
Net loss
Net loss per share attributable to common stockholders—basic and diluted
Weighted-average common shares outstanding—basic and diluted
Net loss per share attributable to common stockholders
Weighted-average common shares outstanding - basic
Weighted-average common shares outstanding - diluted
Unrealized gains on available-for-sale securities
Foreign currency translation adjustment
Total other comprehensive income
Comprehensive loss

Comments